Animal Drug Compounding Market Trends

Animal Drug Compounding Market Trends

Growing regulatory support and comprehensive regulatory guidance are expected to enhance market demand by ensuring safety and efficacy in animal drug compounding. This framework aimed to provide veterinarians and stakeholders with clear guidelines, boosting confidence and adoption rates. The increased regulatory oversight and education efforts further drive market growth by minimizing risks.
 

• For instance, on April 14, 2022, the FDA issued Guidance for Industry #256, titled “Compounding Animal Drugs from Bulk Drug Substances.” This guidance outlines the agency’s approach to enabling veterinarians to access these unapproved drugs to meet the diverse medical needs of the animals they treat. The FDA’s final guidance balances three main objectives: ensuring veterinarians have access to necessary drugs, protecting animals and humans from unsafe drugs, and preserving the integrity of the FDA animal drug approval process. Additionally, the FDA continues to provide extensive education and stakeholder engagement opportunities to address the wide-ranging impact of this guidance anticipating market expansion.
   

Additionally, growing advances in veterinary medicine, rising pet ownership and healthcare spending, and the demand for personalized treatments are driving the need for customized compounded medications, fuelling market growth.